- Advanced search
- Immuno Portal
- Malaria Portal
|No information available.|
|Summary of Clinical Use|
|Secukinumab is approved by the US FDA for the treatment of plaque psoriasis.
Secukinumab also met its clinical endpoints in Phase 2I clinical trial for ankylosing spondylitis (NCT01649375) , and was FDA approved for this indication and psoriatic arthritis [7-8] in January 2016.
The antibody is also in Phase 2 clinical trial for multiple sclerosis (NCT01874340) based on results from experiments in an animal model of the disease (experimental autoimmune encephalomyelitis, EAE) and in vitro human cell assays .
|Mechanism Of Action and Pharmacodynamic Effects|
|Secukinumab targets proinflammatory interleukin (IL)-17A  which is released by T helper 17 cells , and is a validated molecular target for the treatment of chronic immune diseases . Antibody neutralisation of circulating IL-17A reduces symptoms in autoimmune diseases such as plaque psoriasis [6,9], rheumatoid arthritis (note that clinical trial results have not shown significant improvement over placebo ), and chronic noninfectious uveitis.|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)